On June 2, 2022 Median Technologies (ALMDT) reported that it will be presenting an abstract at the 2022 ASCO (Free ASCO Whitepaper) Annual Meeting, June 3-7, McCormick Place, Chicago, IL, USA (exhibition dates: June 4-6) (Press release, MEDIAN Technologies, JUN 2, 2022, View Source [SID1234615456]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the session include:

Abstract # / Poster # – The adjudication rates between readers in Blinded Independent Central Review (BICR) of advanced esophageal cancer trials with or without immune checkpoint initiators as first-line therapy

Session: Gastrointestinal Cancer, Gastroesophageal, Pancreatic and Hepatobiliary
Date: Saturday June 4, 2022
Time: 8:00 AM – 11:00 AM CDT
Place: McCormick Place South, Hall A, Poster Board 27

The study analyzed a pool of advanced esophageal cancer trials with or without immune checkpoint inhibitors, which used RECIST 1.1, and documented the proportion of reader discrepancies, reader performance through monitoring procedures. 4 esophageal cancer BICR trials that included 1,875 patients (8,501 time-points) involving 14 radiologists were analyzed. Trials had an average adjudication rate of 45.28%. The discordances of baseline lesion selection (34.4% of discordances) and lesion measurement (40.3% of discordance) in follow up visits are the main reasons triggering adjudications in esophageal cancer central reading. Appropriate reader training and monitoring are solutions which can not only mitigate a large portion of the commonly encountered reading errors, but also help to reach more consensus on lesion selection and measurement between readers.

The Median’s clinical team will be available at booth #2098, Exhibit Hall A to discuss the abstract results from June 4 to June 6, 9:00 am-5:00 pm.

The ASCO (Free ASCO Whitepaper) Annual Meeting is the world’s premier oncology conference, organized by the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), the largest oncology society in the world. Each year, the ASCO (Free ASCO Whitepaper) conference brings together more than 35,000 oncologists from all around the globe, and is attended by all medical, educational and industrial stakeholders involved in the field of oncology worldwide. More about the ASCO (Free ASCO Whitepaper) Annual Meeting: View Source

On June 2, 2022 Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, reported that Purnanand Sarma, PhD, President and CEO of Immunome, will present at the Jefferies Healthcare Conference on Thursday, June 9, at 2:30 p.m. ET (Press release, Immunomedics, JUN 2, 2022, View Source [SID1234615455]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.

On June 2, 2022 Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, reported that Janux management will present at the 2022 Jefferies Global Healthcare Conference on Friday, June 10, 2022 at 11:00 a.m. ET in New York, New York (Press release, Janux Therapeutics, JUN 2, 2022, View Source [SID1234615454]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation may be accessed via the Investors & Media section of Janux’s website. An archived replay of the webcast will be available on the website for approximately 90 days following the presentation.

On June 2, 2022 ChromaDex Corp. (NASDAQ:CDXC) reported a partnership with Juvenis to conduct cross-border sales of Tru Niagen in South Korea (Press release, ChromaDex, JUN 2, 2022, View Source [SID1234615453]). Juvenis is a Korean healthcare marketing company with a focus on the cosmetic and dietary supplement industries. With strong partnerships in a dynamic and trend-setting Korean market, Juvenis emphasizes products with differentiated science and proven benefits.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Tru Niagen is one of Amazon’s top-selling brands in the Vitamin B3 category for boosting NAD+ levels and features ChromaDex’s proprietary ingredient, Niagen (patented nicotinamide riboside or NR). Between 2019 and 2050, the Republic of Korea is expected to experience the highest increase in its share of older persons, with a 23% increase in those 65 years or older. Nine out of the 10 countries with the largest percentage increase in the share of older persons in the world will be in Eastern and South-Eastern Asia (United Nations).

"As a pioneer of NAD+ research, we are committed to helping communities abroad discover the benefits of cellular energy, defense, repair, and vitality as they age. It is our goal to provide global access to Tru Niagen and are thrilled to partner with Juvenis to bring its proven benefits to South Korea," said Frank Jaksch, Co-Founder and Executive Chairman of ChromaDex.

Just this April 2022, Dr. Charles Brenner (Alfred E Mann Family Foundation Chair in Diabetes and Cancer Metabolism at City of Hope National Medical Center and ChromaDex Chief Scientific Advisor) spoke about innovations in metabolism, including the importance of NR, at K.E.Y. Platform in Seoul, South Korea.

Tru Niagen will be available for sale in the South Korean market on several cross-border marketplaces including NaverSmartStore, 11thStreet, kakaoStore, Gmarket, Auction, and will also be available on www.TruNiagenKorea.com.

"We are pleased to execute a partnership with ChromaDex for the South Korean market," said Dongyeon Kim, CEO of Juvenis. "With a strong collaboration between ChromaDex and Juvenis, we look forward to building a prosperous long-term business together. Above all, we are looking forward to working with ChromaDex to help the Korean community age healthier."

NR, the key ingredient in Tru Niagen, is the world’s most efficient NAD+ precursor on the market, particularly over NMN (nicotinamide mononucleotide). Supplementation with Niagen is backed by 20 published and peer-reviewed clinical trials. Niagen has achieved regulatory acceptance for use in supplements by the US FDA. Additionally, Niagen has been approved for use in food supplements by the European Commission, complementary medicines by the Therapeutic Goods Administration of Australia (TGA), medical foods by the Brazilian Health Regulatory Agency (ANVISA), and medical foods by the Food Standards Australia New Zealand (FSANZ). Tru Niagen has also been approved by Health Canada as a Natural Health Product. Additionally, ChromaDex continues to lead the industry in NAD+ research and recently announced that the ChromaDex External Research Program (CERPTM) reached over 250 material transfer agreements (MTAs) featuring Niagen and other proprietary ingredients.

On June 2, 2022 NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, reported plans to commercially unveil the CosMx Spatial Molecular Imager (SMI) and its new spatial informatics portal during a Spatial Multiomic Symposium, which will be held on Monday, June 6 from noon to 4:00 pm EDT (Press release, NanoString Technologies, JUN 2, 2022, View Source [SID1234615452]). The event will be live-streamed and held in person, and details can be found here: Spatial Multiomics Symposium – NanoString. In addition, scientists will present 20 studies demonstrating the power of NanoString spatial biology platforms during the scientific portion of the AGBT General Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CosMx SMI enables high-resolution imaging of more than 1,000 RNA and over 100 protein analytes within morphologically intact whole tissue sections. The technology combines the power of high-plex profiling with high-resolution imaging, allowing researchers to visualize and quantify gene and protein expression at single cell and subcellular resolutions within both fresh frozen and formalin-fixed paraffin-embedded (FFPE) tissue samples. CosMx SMI serves scientists across the continuum of research using a tunable workflow that can prioritize either unbiased whole-slide imaging at high-plex for discovery or high-throughput biology-driven analysis for translation.

NanoString is dedicated to developing spatial biology solutions for any scale of research. The GeoMx DSP is the leading platform for measuring whole transcriptome at high-throughput in multi-cellular functional regions and the CosMx SMI extends capability to single cell and subcellular resolution across the entire tissue section. Together, GeoMx DSP and CosMx SMI technologies provide unprecedented scientific power for novel spatial discoveries.

Spatial biology experiments are data-intensive, creating up to 1 terabyte of data per sample. NanoString is developing a new cloud-based spatial informatics portal that will provide researchers with a scalable solution to store large GeoMx and CosMx datasets, reduce compute times, and enable secure data sharing and collaboration across institutes.

The Spatial Multiomic Symposium will showcase the application of these powerful tools to resolve biological heterogeneity. Attendees will learn about the latest innovations and will have the opportunity to hear how leading experts are applying these technologies to make novel discoveries in immunology, infectious diseases, oncology and neuroscience.

"We believe spatial biology is the next revolution in life sciences, and we’re honored to bring together experts to showcase cutting-edge spatial technologies and techniques," said Brad Gray, president and CEO, NanoString Technologies. "The volume and quality of NanoString-driven science being presented at AGBT 2022 is a testament to the power of our spatial biology ecosystem."

The Spatial Multiomic Summit Agenda: Speakers and Scientific Presentations

Keynote: Spatial gene expression changes in human skin biology induced from spaceflight: Christopher Mason, Ph.D., Professor; Director, WorldQuant Initiative for Quantitative Prediction; Physiology and Biophysics, Weill Cornell Medicine
Spatially resolved, single cell atlas of human pancreatic islets of Langerhans in type 2 diabetic and healthy controls: Grant Kolar, M.D., Ph.D., Assistant Research Professor Director, Research Microscopy and Histology Core, St. Louis University
Deep spatiotemporal insights into COVID-19: a multi-organ study: Arutha Kulasinghe, Ph.D., National Health and Medical Research Council Research Fellow, The University of Queensland
Spatial reconstruction of joint inflammation in rheumatoid arthritis: Kevin Wei, M.D., Ph.D., Assistant Professor of Medicine, Brigham and Women’s Hospital
Spatially resolved Alzheimer’s disease in mouse model: Miranda Orr, Ph.D., Assistant Professor, Gerontology and Geriatric Medicine, Wake Forest University School of Medicine
To learn more and register for the event, please visit: Spatial Multiomics Symposium – NanoString

At AGBT 2022, 20 posters and oral presentations will showcase unique biological insights generated using NanoString’s spatial platforms. These abstracts include studies exploring spatial biology using the GeoMx DSP and the CosMx SMI platforms.

"As single-cell resolution spatial transcriptomics and proteomics pioneer the next frontier in spatial biology, our understanding of fundamental processes in biology will deepen and perhaps pave the way for next-generation diagnostic and pathology tools," said Joe Beechem, chief scientific officer, NanoString Technologies. "The CosMx SMI system is ideal for deeper single-cell exploration downstream of whole transcriptome analysis carried out on GeoMx DSP and the two systems can essentially be used for complementary experiments on a set of samples."

Several studies and presentations that feature NanoString’s spatial biology platforms are highlighted below.

Oral Presentations

Multicellular spatial neighborhoods in pancreatic cancer remodeled by neoadjuvant treatment will be presented by Will Hwang, M.D., Ph.D., radiation oncologist and research fellow, Massachusetts General Hospital Cancer Center/Harvard Medical School, on June 6 from 6:05-6:25 pm. Discover the unique interaction between malignant cells and nerves/microenvironment during the response to treatment for PDAC, using GeoMx DSP and CosMx SMI platforms.

Building a spatial single-cell multi-omics atlas and cellular interactome for skin cancer will be presented by Quan Nguyen, Ph.D., the University of Queensland on June 7 from 7:50-8:10 pm. Learn how CosMx profiling enables spatial interactome analysis that provides new insights in the development of skin cancer. This will be a comparison of six spatial platforms.

High-plex (> 1000), multi-omic (RNA plus protein), spatial molecular imaging with sub-cellular resolution in FFPE tissue, will be presented by Joe Beechem, Ph.D., chief scientific officer, NanoString Technologies. Concurrent sessions will run from 8:50-9:10 pm on June 8. Learn how high-plex multi-omic (RNA and protein) targets detected in FFPE samples using CosMx SMI, at subcellular and single-cell resolution in >1 million cells from a single slide uncovers novel biological insights that were previously lost in space.

Scientific Posters

Poster: Spatial characterization of the tumor microenvironment in pancreatic cancer with whole transcriptome profiling and high plex single-cell imaging.
David Ting, M.D., Chief Medical Information Officer, Mass General Physicians Organization, Co-Director, MGH Center for Innovation in Digital HealthCare, Assistant Professor, Harvard Medical School
See the origin of exosomes in tumor microenvironments and the effect of their migrations in pancreatic cancer tissues using the CosMx SMI platform.

Poster: Characterization of human brain organoids with single-cell resolution and molecular specificity
Florent Ginhoux, Ph.D., Senior Principal Investigator · Singapore Immunology Network, Agency for Science, Technology and Research
Learn how CosMx single-cell imager enables unique analyses and understanding of human brain organoid cells in space.

Poster: Spatially-mapped quantitative single-cell characterization of PD-L1-related RNA microenvironments in triple-negative breast cancer
Aubrey Thompson, Ph.D., Co-director of the Mayo Clinic Breast Cancer Translational Genomics Program
Learn how CosMx and GeoMx spatial platforms generate consistent data for clinical biomarkers of response to IO therapy.

Poster: Spatial Single Cell characterization of SIV reservoirs in lymphoid tissues and B cell follicles in rhesus macaques
Jake Estes, Ph.D., Professor, VGTI-Vaccine and Gene Therapy Institute; Chief, Division of Pathobiology & Immunology, Oregon National Primate Research Center
Uncover how subcellular localization of SIV RNAs in NHP revealed by CosMx and response to drug targets in infected-cell microenvironments studied using GeoMx DSP provides novel analysis tools for vaccine development.

Poster: High-plex spatial single cell in situ analysis of lung SARS-CoV-2
Arutha Kulasinghe, Ph.D., NHMRC Research Fellow, Queensland University of Technology
Discover the consistent insights in COVID biology and biomarkers uncovered by the CosMx SMI and GeoMx DSP platforms at different scales.

To see the complete list of 2022 AGBT posters and learn more about the data presented on the GeoMx DSP and CosMx SMI platforms, visit NanoString’s AGBT event page.